Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Go back to Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer| (NASDAQ: VIR) | Delayed: 9.57 +0.41 (4.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.16 | 52 Week High | $ | |||
| Open | $9.29 | 52 Week Low | $ | |||
| Day High | $9.63 | P/E | N/A | |||
| Day Low | $9.16 | EPS | $ | |||
| Volume | 1,793,539 | |||||
